At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
TAS-102drug
Likely dose
TAS-102 35 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, OPEN-Label, Non-randomized, Pharmacokinetic Study of TAS-102 in Chinese Patients With Solid Tumors
In Brief
A Phase 1 clinical trial evaluating TAS-102 for Advanced or Metastatic Solid Tumors. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedOct 2014
Primary CompletionOct 2015
Study CompletionJun 2017
TodayJul 2026
First PostedOct 10, 2014
Enrollment StartSep 1, 2014
Primary CompletionOct 1, 2015
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.7 years ago
Interventions
TAS-102drug
TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.